Age 0 3 0 3 B-age
< 4 5 4 5 O
18 6 8 6 8 B-upper_bound
or 9 11 9 11 O
> 12 13 12 13 O
75 14 16 14 16 B-lower_bound
years 17 22 17 22 I-lower_bound

Age 0 3 23 26 B-age
between 4 11 27 34 O
18 12 14 35 37 B-lower_bound
and 15 18 38 41 O
75 19 21 42 44 B-upper_bound
years 22 27 45 50 I-upper_bound

Aspartate 0 9 51 60 B-clinical_variable
aminotransferase 10 26 61 77 I-clinical_variable
( 27 28 78 79 I-clinical_variable
AST 28 31 79 82 I-clinical_variable
) 31 32 82 83 I-clinical_variable
or 33 35 84 86 O
alanine 36 43 87 94 B-clinical_variable
aminotransferase 44 60 95 111 I-clinical_variable
( 61 62 112 113 I-clinical_variable
ALT 62 65 113 116 I-clinical_variable
) 65 66 116 117 I-clinical_variable
> 67 68 118 119 O
2.5 68 71 119 122 B-lower_bound
times 72 77 123 128 I-lower_bound
the 78 81 129 132 I-lower_bound
upper 82 87 133 138 I-lower_bound
limits 88 94 139 145 I-lower_bound
of 95 97 146 148 I-lower_bound
normal 98 104 149 155 I-lower_bound

CCR5 0 4 156 160 B-chronic_disease
tropic 5 11 161 167 I-chronic_disease
virus 12 17 168 173 I-chronic_disease

CD4 0 3 174 177 B-clinical_variable
count 4 9 178 183 I-clinical_variable
nadir 10 15 184 189 I-clinical_variable
< 16 17 190 191 O
250 18 21 192 195 B-upper_bound
cells 22 27 196 201 I-upper_bound
/ 27 28 201 202 I-upper_bound
mm3 28 31 202 205 I-upper_bound

CD4 0 3 206 209 B-clinical_variable
count 4 9 210 215 I-clinical_variable
nadir 10 15 216 221 I-clinical_variable
≥ 16 17 222 223 O
250 18 21 224 227 B-lower_bound
cells 22 27 228 233 I-lower_bound
/ 27 28 233 234 I-lower_bound
mm3 28 31 234 237 I-lower_bound

CD4 0 3 238 241 B-clinical_variable
nadir 4 9 242 247 I-clinical_variable
≥ 10 11 248 249 O
500 12 15 250 253 B-lower_bound
cells 16 21 254 259 I-lower_bound
/ 21 22 259 260 I-lower_bound
mm3 22 25 260 263 I-lower_bound

CYP3A 0 5 264 269 B-treatment
inducers 6 14 270 278 I-treatment
( 15 16 279 280 O
such 16 20 280 284 O
as 21 23 285 287 O
rifampin 24 32 288 296 B-treatment
, 32 33 296 297 O
carbamazepine 34 47 298 311 B-treatment
, 47 48 311 312 O
phenobarbital 49 62 313 326 B-treatment
and 63 66 327 330 O
phenytoin 67 76 331 340 B-treatment
) 76 77 340 341 O

CYP3A 0 5 342 347 B-treatment
inhibitors 6 16 348 358 I-treatment
( 17 18 359 360 O
such 18 22 360 364 O
as 23 25 365 367 O
ketoconazole 26 38 368 380 B-treatment
, 38 39 380 381 O
itraconazole 40 52 382 394 B-treatment
, 52 53 394 395 O
clarithromycin 54 68 396 410 B-treatment
, 68 69 410 411 O
nefazodone 70 80 412 422 B-treatment
, 80 81 422 423 O
and 82 85 424 427 O
telithromycin 86 99 428 441 B-treatment
) 99 100 441 442 O

Chronic 0 7 443 450 B-chronic_disease
active 8 14 451 457 I-chronic_disease
hepatitis 15 24 458 467 I-chronic_disease
B 25 26 468 469 I-chronic_disease
infection 27 36 470 479 I-chronic_disease
as 37 39 480 482 O
defined 40 47 483 490 O
by 48 50 491 493 O
presence 51 59 494 502 O
of 60 62 503 505 O
HBsAg 63 68 506 511 B-clinical_variable

Concomitant 0 11 512 523 O
use 12 15 524 527 O
of 16 18 528 530 O
drugs 19 24 531 536 B-treatment
known 25 30 537 542 O
to 31 33 543 545 O
impact 34 40 546 552 O
or 41 43 553 555 O
be 44 46 556 558 O
impacted 47 55 559 567 O
in 56 58 568 570 O
terms 59 64 571 576 O
of 65 67 577 579 O
pharmacokinetics 68 84 580 596 O
or 85 87 597 599 O
drug 88 92 600 604 O
- 92 93 604 605 O
drug 93 97 605 609 O
interactions 98 110 610 622 O
with 111 115 623 627 O
either 116 122 628 634 O
raltegravir 123 134 635 646 B-treatment
or 135 137 647 649 O
maraviroc 138 147 650 659 B-treatment

DNA 0 3 660 663 O
trofile 4 11 664 671 O
if 12 14 672 674 O
no 15 17 675 677 O
trofile 18 25 678 685 O
/ 25 26 685 686 O
tropism 26 33 686 693 O
test 34 38 694 698 O
available 39 48 699 708 O
and 49 52 709 712 O
CD4 53 56 713 716 B-clinical_variable
nadir 57 62 717 722 I-clinical_variable
250 63 66 723 726 B-lower_bound
- 66 67 726 727 O
499 67 70 727 730 B-upper_bound
cells 71 76 731 736 I-upper_bound
/ 76 77 736 737 I-upper_bound
mm3 77 80 737 740 I-upper_bound

Enrollment 0 10 741 751 O
in 11 13 752 754 O
an 14 16 755 757 O
experimental 17 29 758 770 O
protocol 30 38 771 779 O
having 39 45 780 786 O
received 46 54 787 795 O
investigational 55 70 796 811 B-treatment
agents 71 77 812 818 I-treatment
( 78 79 819 820 O
antiretroviral 79 93 820 834 B-treatment
or 94 96 835 837 O
non 97 100 838 841 B-treatment
- 100 101 841 842 I-treatment
antiretroviral 101 115 842 856 I-treatment
) 115 116 856 857 O
within 117 123 858 864 O
30 124 126 865 867 B-upper_bound
days 127 131 868 872 I-upper_bound
of 132 134 873 875 O
study 135 140 876 881 O
enrollment 141 151 882 892 O

HIV 0 3 893 896 B-clinical_variable
RNA 4 7 897 900 I-clinical_variable
≤ 8 9 901 902 O
50 10 12 903 905 B-upper_bound
copies 13 19 906 912 I-upper_bound
/ 19 20 912 913 I-upper_bound
ml 20 22 913 915 I-upper_bound
for 23 26 916 919 O
≥ 27 28 920 921 O
12 29 31 922 924 B-lower_bound
months 32 38 925 931 I-lower_bound
while 39 44 932 937 O
taking 45 51 938 944 O
any 52 55 945 948 O
ART 56 59 949 952 B-treatment
regimen 60 67 953 960 I-treatment

HIV-1 0 5 961 966 B-chronic_disease
infection 6 15 967 976 I-chronic_disease

History 0 7 977 984 O
of 8 10 985 987 O
any 11 14 988 991 O
malignancy 15 25 992 1002 B-cancer
except 26 32 1003 1009 O
non 33 36 1010 1013 B-cancer
- 36 37 1013 1014 I-cancer
melanoma 37 45 1014 1022 I-cancer
skin 46 50 1023 1027 I-cancer
cancer 51 57 1028 1034 I-cancer

Inducers 0 8 1035 1043 O
of 9 11 1044 1046 O
UGT1A1 12 18 1047 1053 O
( 19 20 1054 1055 O
such 20 24 1055 1059 O
as 25 27 1060 1062 O
rifampin 28 36 1063 1071 B-treatment
, 36 37 1071 1072 O
phenytoin 38 47 1073 1082 B-treatment
, 47 48 1082 1083 O
phenobarbital 49 62 1084 1097 B-treatment
rifabutin 63 72 1098 1107 I-treatment
, 72 73 1107 1108 O
St. 74 77 1109 1112 B-treatment
John 78 82 1113 1117 I-treatment
's 82 84 1117 1119 I-treatment
wort 85 89 1120 1124 I-treatment
) 89 90 1124 1125 O

One 0 3 1126 1129 B-clinical_variable
virologic 4 13 1130 1139 I-clinical_variable
blip 14 18 1140 1144 I-clinical_variable
≤ 19 20 1145 1146 O
400 21 24 1147 1150 B-upper_bound
copies 25 31 1151 1157 I-upper_bound
/ 31 32 1157 1158 I-upper_bound
ml 32 34 1158 1160 I-upper_bound
permissible 35 46 1161 1172 O
within 47 53 1173 1179 O
the 54 57 1180 1183 O
12 58 60 1184 1186 B-upper_bound
months 61 67 1187 1193 I-upper_bound

Subject 0 7 1194 1201 O
has 8 11 1202 1205 O
a 12 13 1206 1207 O
history 14 21 1208 1215 O
or 22 24 1216 1218 O
current 25 32 1219 1226 O
evidence 33 41 1227 1235 O
of 42 44 1236 1238 O
any 45 48 1239 1242 O
condition 49 58 1243 1252 O
, 58 59 1252 1253 O
therapy 60 67 1254 1261 B-treatment
, 67 68 1261 1262 O
laboratory 69 79 1263 1273 O
abnormality 80 91 1274 1285 O
or 92 94 1286 1288 O
other 95 100 1289 1294 O
circumstance 101 113 1295 1307 O
that 114 118 1308 1312 O
might 119 124 1313 1318 O
interfere 125 134 1319 1328 O
with 135 139 1329 1333 O
the 140 143 1334 1337 O
patient 144 151 1338 1345 O
's 151 153 1345 1347 O
participation 154 167 1348 1361 O
for 168 171 1362 1365 O
the 172 175 1366 1369 O
full 176 180 1370 1374 O
duration 181 189 1375 1383 O
of 190 192 1384 1386 O
the 193 196 1387 1390 O
study 197 202 1391 1396 O
, 202 203 1396 1397 O
such 204 208 1398 1402 O
that 209 213 1403 1407 O
it 214 216 1408 1410 O
is 217 219 1411 1413 O
not 220 223 1414 1417 O
in 224 226 1418 1420 O
the 227 230 1421 1424 O
best 231 235 1425 1429 O
interest 236 244 1430 1438 O
of 245 247 1439 1441 O
the 248 251 1442 1445 O
patient 252 259 1446 1453 O
to 260 262 1454 1456 O
participate 263 274 1457 1468 O

Subject 0 7 1469 1476 O
requires 8 16 1477 1485 O
or 17 19 1486 1488 O
is 20 22 1489 1491 O
anticipated 23 34 1492 1503 O
to 35 37 1504 1506 O
require 38 45 1507 1514 O
any 46 49 1515 1518 O
of 50 52 1519 1521 O
the 53 56 1522 1525 O
prohibited 57 67 1526 1536 O
medications 68 79 1537 1548 B-treatment
noted 80 85 1549 1554 O
in 86 88 1555 1557 O
the 89 92 1558 1561 O
protocol 93 101 1562 1570 O

Women 0 5 1571 1576 B-gender

are 0 3 1577 1580 O
currently 4 13 1581 1590 O
pregnant 14 22 1591 1599 B-pregnancy
or 23 25 1600 1602 O
breastfeeding 26 39 1603 1616 O

are 0 3 1617 1620 O
of 4 6 1621 1623 O
child 7 12 1624 1629 O
- 12 13 1629 1630 O
bearing 13 20 1630 1637 O
age 21 24 1638 1641 B-age
and 25 28 1642 1645 O
do 29 31 1646 1648 O
not 32 35 1649 1652 B-contraception_consent
agree 36 41 1653 1658 I-contraception_consent
to 42 44 1659 1661 I-contraception_consent
remain 45 51 1662 1668 I-contraception_consent
abstinent 52 61 1669 1678 I-contraception_consent
or 62 64 1679 1681 I-contraception_consent
use 65 68 1682 1685 I-contraception_consent
( 69 70 1686 1687 I-contraception_consent
or 70 72 1687 1689 I-contraception_consent
have 73 77 1690 1694 I-contraception_consent
their 78 83 1695 1700 I-contraception_consent
partner 84 91 1701 1708 I-contraception_consent
use 92 95 1709 1712 I-contraception_consent
) 95 96 1712 1713 I-contraception_consent
an 97 99 1714 1716 I-contraception_consent
acceptable 100 110 1717 1727 I-contraception_consent
method 111 117 1728 1734 I-contraception_consent
of 118 120 1735 1737 I-contraception_consent
birth 121 126 1738 1743 I-contraception_consent
control 127 134 1744 1751 I-contraception_consent
throughout 135 145 1752 1762 O
the 146 149 1763 1766 O
study 150 155 1767 1772 O

